TABLE 3.
Baseline Characteristics and laboratory findings on admission of COVID‐19 patients of normal BMI with and without NAFLD
| NAFLD (n = 30) | Non‐NAFLD (n=78) | p value | |
|---|---|---|---|
| Sex (male/female) | 15/15 | 45/33 | 0.471 |
| Age, y, median (range) | 47 (27–72) | 43 (21–84) | 0.929 |
| Hypertension (n, %) | 8 (26.7%) | 9 (11.5%) | 0.101 |
| CVD (n, %) | 2 (6.7%) | 3 (3.8%) | 0.616 |
| Diabetes (n, %) | 3 (10.0%) | 4 (5.1%) | 0.628 |
| Chronic liver disease (n, %) | 3 (10.0%) | 4 (5.1%) | 0.628 |
| Fever (n, %) | 25 (83.3%) | 56 (71.8%) | 0.173 |
| Cough (n, %) | 26 (86.7%) | 55 (70.5%) | 0.082 |
| Fatigue (n, %) | 18 (60.0%) | 34 (43.6%) | 0.126 |
| Expectoration (n, %) | 16 (53.3%) | 27 (34.6%) | 0.075 |
| WBC, x109/L, median (range) | 4.6 (2.3–9.35) | 4.5 (0.8–10.4) | 0.384 |
| Lys count, x109/L, median (range) | 1.0 (0.4–2.7) | 1.2 (0.1–3.1) | 0.131 |
| ALT, U/L, median (range) | 26.2 (12.1–93.7) | 15.8 (4.9–58.4) | 0.000 |
| AST, U/L, median (range) | 25.7 (11.5–58.5) | 22.6 (12.6–69.0) | 0.009 |
| Total bilirubin, μmol/L, medium (range) | 12.6 (6.9–30.1) | 9.7 (4.0–26.1) | 0.010 |
| Creatinine, μmol/L, medium (range) | 52.0 (30.0–83.3) | 50.9 (20.6–213.9) | 0.970 |
| Creatine kinase, U/L, medium (range) | 104.7 (17.4–513.3) | 68.4 (22.7–449.5) | 0.054 |
| Creatine kinase‐MB, U/L, medium (range) | 11.2 (1.1–34.1) | 9.7 (0.3–35.2) | 0.259 |
| CRP, mg/L, median (range) | 20.8 (1.0–94.9) | 11.1 (0.1–101.9) | 0.012 |
| Total cholesterol, mg/dL, medium (range) | 3.9 (2.5–6.9) | 3.8 (2.5–5.9) | 0.380 |
| LDL cholesterol, mg/dL, medium (range) | 2.7 (1.6–5.9) | 2.6 (1.4–4.4) | 0.344 |
| HDL cholesterol, mg/dL, medium (range) | 0.8 (0.6–1.2) | 0.9 (0.5–1.6) | 0.008 |
| Triglyceride, mg/dL, medium (range) | 1.4 (0.9–6.1) | 0.9 (0.1–2.7) | 0.000 |
| PCT, ≥0.05 ng/mL (n, %) | 9 (30.0%) | 16 (20.5%) | 0.295 |
| Chest CT positive rate (n, %) | 29 (96.7%) | 74 (94.9%) | 1.000 |
| Chest CT with ground‐glass change | 18 (60%) | 31 (39.7%) | 0.058 |
| Virus shedding time (days) | 17 (3–38) | 17 (6–53) | 0.989 |
| Length of hospital stay (days) | 16.5 (5–37) | 16 (5–37) | 0.695 |
Abbreviations: NAFLD, non‐alcoholic fatty liver disease; y, years; CVD, cardiovascular disease; WBC, white blood cell count; Lys, lymphocyte; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C reactive protein; PCT, procalcitonin.